Journal
NEUROSCIENCE BULLETIN
Volume 32, Issue 6, Pages 591-596Publisher
SPRINGER
DOI: 10.1007/s12264-016-0067-0
Keywords
Alzheimer's disease; Therapy; Benfotiamine; PiB-PET; Amyloid deposition
Categories
Funding
- Ministry of Science and Technology of China [2014ZX09101005-005]
- National Natural Science Foundation of China [81071019]
- National Key Basic Research Program of China [2011CBA00400]
- Natural Science Foundation of Shanghai Municipality, China [13JC1401500]
- Fund for Medical Emerging Cutting-Edge Technology in Shanghai of China [SHDC12012114]
Ask authors/readers for more resources
To date, we still lack disease-modifying therapies for Alzheimer's disease (AD). Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine (300 mg daily) over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B (PiB-PET) and exhibited positive imaging with beta-amyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improvement as assayed by the Mini-Mental Status Examination (MMSE) with an average increase of 3.2 points at month 18 of benfotiamine administration. The three patients who received follow-up PiB-PET had a 36.7% increase in the average standardized uptake value ratio in the brain compared with that in the first scan. Importantly, the MMSE scores of these three had an average increase of 3 points during the same period. Benfotiamine significantly improved the cognitive abilities of mild to moderate AD patients independently of brain amyloid accumulation. Our study provides new insight to the development of disease-modifying therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available